Department of Opthalmology, Faculty of Medicine, University of Yamanashi, Shimokato, Yamanashi, Japan.
Retina. 2010 Nov-Dec;30(10):1616-21. doi: 10.1097/IAE.0b013e3181e587e3.
To investigate whether there is an association of the LOC387715 A69S genotype with visual prognosis after photodynamic therapy in eyes with polypoidal choroidal vasculopathy (PCV).
Photodynamic therapy was repeated every 3 months until the disappearance of angiographic signs of active lesions in 71 eyes of 71 patients with PCV who were followed-up for at least 12 months. All patients were genotyped for LOC387715 A69S polymorphism (rs10490924, risk-allele T).
Although there was no statistically significant difference in the mean baseline visual acuity (P = 0.53) among the 3 genotypes, there was a statistically significant difference in the visual acuity both at the 12-month and final visits (P = 0.002 and P < 0.001, respectively) with the poorer acuity in patients with the higher "T-"allele frequency. "T" allele was more frequently observed in those with the recurred PCV lesions (odds ratio: 5.8, 95% confidential interval: 2.3-15.1, T vs. G).
There is a pharmacogenetic association between the LOC387715 A69S variant and the long-term results after photodynamic therapy in eyes with PCV. The LOC387715 A69S genotype is of clinical importance to predict the visual prognosis after photodynamic therapy in eyes with PCV. These results should be confirmed or refuted by replication studies.
研究 LOC387715 A69S 基因型是否与息肉状脉络膜血管病变（PCV）患者光动力疗法（PDT）后的视力预后有关。
对 71 例（71 只眼）PCV 患者进行 PDT 治疗，每 3 个月重复一次，直至活动性病变的血管造影征象消失，随访至少 12 个月。对所有患者进行 LOC387715 A69S 多态性（rs10490924，风险等位基因 T）的基因分型。
尽管 3 种基因型的基线平均视力（P = 0.53）之间没有统计学上的显著差异，但在 12 个月和最终随访时的视力（P = 0.002 和 P < 0.001）均有统计学差异，携带较高 T-等位基因频率的患者视力更差。在复发性 PCV 病变患者中更常观察到 T 等位基因（比值比：5.8，95%置信区间：2.3-15.1，T 与 G）。
LOC387715 A69S 变异与 PCV 患者 PDT 后长期结果之间存在药物遗传学关联。LOC387715 A69S 基因型对预测 PCV 患者 PDT 后的视力预后具有临床重要意义。这些结果需要通过复制研究来证实或反驳。
